stockrowMyomo, Inc.
MYO Healthcare Medical Devices
Myomo, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $40.9 million, up 25.7% from fiscal 2024.
- Revenue
- +21.3%
- EPS
- +18.2%
- Free cash flow
- +80.0%
- Total debt
- +199.5%
Quarter to June 2026, against a year earlier
Follow MYO
Alert me
Myomo, Inc. (MYO) EV/Sales
As of 5 November 2026, Myomo, Inc. (MYO) trades at a EV/Sales of 1.1×. Over the past ten years it has ranged from −1.4× (April 2020) to 41.9× (November 2017); the current reading is higher than 36% of that period. That is below the Medical Devices industry median of 2.7× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.8× | (88.20%) |
| FY2024 | 6.7× | (2.77%) |
| FY2023 | 6.9× | — |
| FY2022 | −0.1× | — |
| FY2021 | 1.8× | 33.06% |
| FY2020 | 1.4× | 64.36% |
| FY2019 | 0.8× | (83.73%) |
| FY2018 | 5.1× | 94.61% |
| FY2017 | 2.6× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.0× | 60.04% |
| Mar 2026 | 0.6× | (21.91%) |
| Dec 2025 | 0.8× | 14.13% |
| Sep 2025 | 0.7× | (63.80%) |
| 36 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| XTNT Xtant Medical Holdings, Inc. compare | 0.5× |
| SNWV Sanuwave Health Inc. compare | 0.7× |
| CVRX CVRx, Inc. compare | 0.7× |
| TELA TELA Bio, Inc. compare | 1.0× |
| LNSR LENSAR, Inc. compare | 1.0× |
| MYO Myomo, Inc. | 1.1× |
| SRTS Sensus Healthcare, Inc. compare | 2.2× |
| MDAI Spectral AI, Inc. compare | 2.7× |
| COCH Envoy Medical, Inc. compare | 389× |
| Medical Devices industry median | 2.7× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)